<DOC>
	<DOCNO>NCT00350727</DOCNO>
	<brief_summary>This study conduct characterize safety/tolerability pazopanib lapatinib administer combination enzyme-inducing anticonvulsant patient recurrent Grade III IV malignant glioma .</brief_summary>
	<brief_title>Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma</brief_title>
	<detailed_description>This study conduct characterize safety/tolerability pazopanib lapatinib administer combination enzyme-inducing anticonvulsant patient recurrent Grade III IV malignant glioma .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Phase I Patients EIAC minimum 15 day . Patients may one anticonvulsant ( AC ) . At least one ACs must EIAC . Patients anaplastic astrocytoma , anaplastic oligodendroglioma , mixed anaplastic oligoastrocytoma , glioblastoma multiforme , gliosarcoma recurrence Patients whose diagnostic pathology confirm pathology need rebiopsy Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation Grade III IV malignant glioma Phase II Patients must histologically confirm glioblastoma multiforme gliosarcoma first second recurrence . Patients may receive two prior cytotoxic chemotherapy contain regimen . Patients must receive prior treatment VEGFR , ErbB1 , ErbB2 inhibitor include limited PTK787 , Sorafenib , Sutent , Tarceva , Iressa , Erbitux , Herceptin . Prior Avastin therapy permit provide three month elapse Day 1 , Treatment Period 1 . Tumor tissue must analyze PTEN epidermal growth factor receptor ( EGFR ) vIII prior dose . Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation Grade IV malignant glioma . Patients must EIAC . NOTE : Once ( optimally tolerate regimen ) OTR Phase I determine patient expand cohort complete 1 treatment period patient EIAC may enrol Phase II component study . Phase I II Male female , age least 18 year age . Eastern Cooperative Oncology Group ( ECOG ) status 0 1 per protocol . Clinical lab result per protocol Has leave ventricular ejection fraction ( LVEF ) least 50 % base echocardiogram ( ECHO ) Multi Gated Aquisition ( MUGA ) within institutional normal range . Adequate renal function Creatinine clearance 50 mL/min calculate CockcroftGault formula per protocol . Urine Protein Creatinine ( UPC ) ratio less equal 1 per protocol . Able swallow retain oral medication . A woman eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is postmenopausal ( total cessation menses least 1 year ) Childbearing potential , negative serum pregnancy test screening , agree use adequate contraception . Acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device ( IUD ) document failure rate le 1 % per year . Vasectomized partner sterile prior female patient 's entry sole sexual partner female . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . A man female partner childbearing potential eligible enter participate study use barrier method contraception abstinence study . If sexually active , patient continue recommend contraceptive measure duration treatment 28 day follow discontinuation therapy . Signed informed consent approve Institutional Review Board prior patient entry . Exclusion criterion : Poorly control hypertension per protocol . NOTE : Initiation adjustment BP medication permit prior study entry provide patient two consecutive BP reading less 140/90 mmHg separate minimum 24 hr . These reading need collect prior enrolment . Concurrent severe and/or uncontrolled medical disease ( e.g . uncontrolled diabetes , congestive cardiac failure , poorly control hypertension , history labile hypertension , history poor compliance antihypertensive regimen , chronic renal disease , active uncontrolled infection ) could compromise participation study . History myocardial infarction , admission unstable angina , cardiac angioplasty stenting within three month Day 1 , Treatment Period 1 . Has Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system per protocol . QTc prolongation define correct QT ( QTc ) interval great equal 470 millisecond . History venous arterial thrombosis within 3 month Day 1 , Treatment Period 1 . Current use therapeutic warfarin . NOTE : low molecular weight heparin prophylactic lowdose warfarin permit ; however , prothrombin time/partial thromboplastin time ( PT/PTT ) must meet inclusion criterion . Excessive risk bleeding define stroke within prior 6 month , history central nervous system ( CNS ) intraocular bleed , septic endocarditis . Evidence intratumor hemorrhage pretreatment diagnostic imaging , except stable postoperative Grade 1 hemorrhage . Active systemic bleeding , gastrointestinal bleeding gross hematuria . Female patient pregnant breast feed . Acute chronic liver disease ( i.e. , hepatitis , cirrhosis ) . Patients receive investigational drug le 21days prior Day 1 , Treatment Period 1 , recover toxic effect therapy . Patients receive chemotherapy less equal 21days prior ( 6 week prior nitrosourea mitomycin C ) Day 1 , Treatment Period 1 , recover toxic effect therapy . Patients receive radiation therapy less equal 12 week prior Day 1 , Treatment Period 1 , recover toxic effect therapy per protocol . Patients receive biologic , immunotherapeutic cytostatic agent less equal 14 day prior Day 1 , Treatment Period 1 , recover toxic effect therapy . Patient le 3 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention . Patients history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Surgical resection brain tumor surgery less equal 21 day prior Day 1 , Treatment Period 1 , recover side effect procedure . Patients undergo stereotactic biopsy less equal 14 day prior Day 1 Treatment Period 1 , recover side effect procedure . Patients Grade intraparenchymal CNS hemorrhage . Exceptions include Grade 1 intraparenchymal hemorrhage immediate postoperative period , Grade 1 intraparenchymal hemorrhage stable least 3 month . Patients unwilling unable comply protocol . Any serious and/or unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere patient safety obtain informed consent . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism excretion study drug . Has unresolved bowel obstruction diarrhea . Psychological , familial , sociological , geographical condition permit compliance protocol . Is specifically prohibit medication require medication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>relapse</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>glioblastoma</keyword>
</DOC>